Neurocrine Biosciences Advances Schizophrenia Treatment with New Phase 2a Clinical Study
Neurocrine Biosciences (NBIX) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neurocrine Biosciences has announced the initiation of a Phase 2a clinical study titled A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization. This study aims to evaluate the efficacy of NBI-1117570 in improving behavioral and psychological symptoms in adult schizophrenia patients requiring hospitalization. The study’s outcomes are significant as they may address unmet needs in schizophrenia treatment.
The study will test NBI-1117570, an investigational oral drug, at two dose levels compared with a placebo. The drug is designed to target symptoms of schizophrenia effectively, offering a possibly novel treatment option.
This is a randomized, double-blind, placebo-controlled trial conducted using a parallel intervention model. Triple masking ensures that participants, caregivers, investigators, and outcome assessors remain uninformed about treatment assignments, maintaining scientific rigor. The treatment’s primary goal is therapeutic intervention.
The study is set to begin on December 15, 2025, with primary completion and study completion dates yet to be announced. This marked update indicates progression in the company’s clinical pipeline.
If successful, the study could enhance Neurocrine Biosciences’ portfolio and appeal to investors, given the competitive landscape in schizophrenia therapeutics. Industry focus on innovative treatments and investor interest in Neurocrine’s clinical developments suggest potential stock movement following further updates.
The trial remains in its early stages, and more details are available on the ClinicalTrials portal, where updates will be shared as the study progresses.
To learn more about NBIX’s potential, visit the Neurocrine Biosciences drug pipeline page.
